GLS-010 plus platinum chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, placebo-controlled phase III study compares GLS-010 plus platinum-containing chemotherapy, with or without bevacizumab, as initial therapy for persistent, recurrent, or metastatic cervical cancer. Eligible patients are adults with PD-L1 positive tumors and measurable disease who have not received prior systemic therapy for this stage. Participants are randomly assigned to receive GLS-010 or placebo alongside chemotherapy until disease progression, unacceptable toxicity, or other trial end criteria. Safety and efficacy are assessed through predefined endpoints typical of first-line cervical cancer trials. The trial is led by Guangzhou Gloria Biosciences with collaboration at a Shanghai site.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed the informed consent form.
2. Women aged ≥ 18 and ≤ 75 years.
3. ECOG of 0 or 1.
4. Life expectancy ≥ 12 weeks.
5. Cervical cancer patients with histologically confirmed PD-L1 positive (CPS ≥ 1),.The histological types include squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma.
6. No prior systemic therapy for persistent, recurrent or metastatic (\[FIGO\] Stage IVB) disease,not amenable to curative surgery or concurrent chemoradiotherapy.
7. At least one measurable tumor lesion per RECIST v1.1; lesions previously treated with radiotherapy or other loco-regional therapy are not considered as target lesions unless the lesion has unequivocal progression or the biopsy is obtained to confirm maligancy.
8. Subjects must have adequate organ function.
9. Female subjects of childbearing potential must have a negative serum pregnancy test prior to the first dose. Female subject of childbearing potential must use acceptable effective methods of contraception from screening and must agree to continue these precautions until 6 months after the last dose of study drug.

Exclusion Criteria:

1. Patients with the opportunity to be cured by surgery and radiotherapy.
2. Received with concurrent chemoradiotherapy, adjuvant chemotherapy,neo- adjuvant chemotherapy within 4 weeks prior to randomization.
3. Active central nervous system (CNS) metastasis.
4. Patients with other malignancies prior to randomization. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, transitional cell carcinoma of urothelial cancer, or carcinoma in situ (e.g. breast cancer) that have been cured are not excluded.
5. Has an active autoimmune disease that has required systemic treatment.
6. With active serious infections.
7. Subjects with HIV infection ,active hepatitis B virus infection, active hepatitis C virus infection,active tuberculosis infection,active syphilis .
8. Has not recovered adequately from toxicity and/or complications from surgery prior to randomization.
9. . .
10. Has a contraindication or hypersensitivity to any component of cisplatin, carboplatin, paclitaxel, or bevacizumab.
11. Have received any investigational treatment in other clinical trials within 4 weeks prior to randomization.
12. Pregnant or lactating women,or women may become pregnant during treatment.
13. Has had an allogeneic tissue/solid organ/ hematopoietic stem cells transplant.
14. History of nervous system and mental disease. History of drug abuse.
15. The patient is not suitable to participate the study in the opinion of the investigator.

Where it's running

• Fudan University Shanghai Cancer Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

• Bevacizumab for severe HHT-related nosebleeds

  This study tests whether bevacizumab can help people with hereditary hemorrhagic telangiectasia who have severe nosebleeds.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07828015

• Torvutatug samrotecan with or without bevacizumab as maintenance in platinum-sensitive relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This study tests torvutatug samrotecan, with or without bevacizumab, to see if it helps people with platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer stay cancer-free longer after their last platinum therapy.

  Recruiting at 3 sites Phase 3 AstraZeneca · Anchorage, Alaska and 123 other locations · NCT07816666

• Trastuzumab plus bevacizumab vs bevacizumab alone as first-line maintenance therapy for ovarian cancer

  This trial tests whether adding trastuzumab to bevacizumab maintenance helps people with epithelial ovarian cancer after initial platinum-based therapy.

  Recruiting at 3 sites Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 2 other locations · NCT07779538

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.